The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Official Title: A Phase II Study of Three Hour, Weekly Infusion of ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Study ID: NCT00147212
Brief Summary: The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.
Detailed Description: * Treatment with trabectedin will be given once a week for three consecutive weeks with one week of no treatment. This four week period constitutes one cycle. * Trabectedin is given as an infusion through a central venous catheter and is administered over 3 hours. * On day 1 of each cycle a history, physical exam and blood tests will be performed and trabectedin will be administered. * On day 8 and day 15 of each cycle blood work will be performed and trabectedin will be administered. * Patients will continue to receive trabectedin as long as there is no disease progression or unacceptable side effects. * Scans (CT, MRI or bone) or x-rays may be done while the patient is on the trial at the discretion of the physician.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Masachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Name: Dror Michaelson, MD
Affiliation: Massachusetts General Hospital
Role: PRINCIPAL_INVESTIGATOR